Vitamin C restores behavioral deficits and amyloid-β oligomerization without affecting plaque formation in a mouse model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 26, Issue 1, 2011, Pages 7-18

  Murakami, Kazuma ^a,b   Murata, Nakaba ^a,c   Ozawa, Yusuke ^a   Kinoshita, Noriaki ^d   Irie, Kazuhiro ^b   Shirasawa, Takuji ^e   Shimizu, Takahiko ^a,c  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d Immuno Biological Laboratories Co Ltd   (Japan)

^e JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; amyloid ; anxiety; hyperactivity; oligomer; vitamin C

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ASCORBIC ACID; SYNAPTOPHYSIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; BRAIN DAMAGE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MAZE TEST; MOUSE; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION;

EID: 79956193119     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101971     Document Type: Article

References (49)

1. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cere-brovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890. (Pubitemid 14104991)
2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245-4249. (Pubitemid 15053619)
3. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112. (Pubitemid 46432529)
4. Murakami K, Masuda Y, Shirasawa T, Shimizu T, Irie K (2010) The turn formationatpositions 22and23inthe 42-mer amyloid beta peptide: the emerging role in the pathogene-sis of Alzheimer's disease. Geriatr Gerontol Int 10 Suppl 1, S169-S179.
5. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocam-pal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
6. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease.J Biol Chem 284, 4749-4753.
7. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321, 823-829. (Pubitemid 46762675)
8. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41, 17-24. (Pubitemid 27057088)
9. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, deCalignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
10. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3, 205-214.
11. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7, 548-554. (Pubitemid 33127140)
12. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21, 172-188. (Pubitemid 351219718)
13. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229. (Pubitemid 34686103)
14. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B (1998) Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 13, 749-754. (Pubitemid 28542706)
15. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR (1998) Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 13, 840-845. (Pubitemid 28564482)
16. Paleologos M, Cumming RG, Lazarus R (1998) Cohort study of vitaminCintake and cognitive impairment. Am J Epidemiol 148, 45-50. (Pubitemid 28317544)
17. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M (2001) Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30, 235-241. (Pubitemid 32684904)
18. Medina S, Martinez M, Hernanz A (2002) Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res 36, 1179-1184. (Pubitemid 35230238)
19. Harrison FE, Hosseini AH, McDonald MP, May JM (2009) Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol Biochem Behav 93, 443-450.
20. Harrison FE, Allard J, Bixler R, Usoh C, Li L, May JM, McDonald MP (2009) Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr Neurosci 12, 203-218.
21. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058. (Pubitemid 30365675)
22. Murakami K, Inagaki J, Saito M, Ikeda Y, Tsuda C, Noda Y, Kawakami S, Shirasawa T, Shimizu T (2009) Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. Biochem Biophys Res Commun 382, 457-461.
23. Murata N, Murakami K, Ozawa Y, Kinoshita N, Irie K, Shira-sawa T, Shimizu T (2010) Silymarin Attenuated the Amyloid beta Plaque Burden and Improved Behavioral Abnormalities in an Alzheimer's Disease Mouse Model. Biosci Biotechnol Biochem 74, 2299-2306.
24. Massie HR, Aiello VR, Doherty TJ (1984) Dietary vitamin C improves the survival of mice. Gerontology 30, 371-375. (Pubitemid 15176249)
25. Massip L, Garand C, Paquet ER, Cogger VC, O'Reilly JN, Tworek L, Hatherell A, Taylor CG, Thorin E, Zahradka P, Le Couteur DG, Lebel M (2010) Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J 24, 158-172.
26. Kondo Y, Inai Y, Sato Y, Handa S, Kubo S, Shimokado K, Goto S, Nishikimi M, Maruyama N, Ishigami A (2006) Senescence marker protein30functionsasgluconolactonaseinL-ascorbic acid biosynthesis, and its knockout mice are prone to scurvy. Proc Natl Acad Sci USA 103, 5723-5728.
27. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11, 1311-1318.
28. Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L (2008) Enkephalin elevations contribute to neuronal and behavioral impairments in a trans-genic mouse model of Alzheimer's disease. J Neurosci 28, 5007-5017.
29. Satoh Y, Endo S, Ikeda T, Yamada K, Ito M, Kuroki M, Hiramoto T, Imamura O, Kobayashi Y, Watanabe Y, Itohara S, Takishima K (2007) Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. J Neurosci 27, 10765-10776. (Pubitemid 47535863)
30. Steward O, Loesche J, Horton WC (1977) Behavioral correlates of denervation and reinnervation of the hippocampal formation of the rat: open field activity and cue utilization following bilateral entorhinal cortex lesions. Brain Res Bull 2, 41-48. (Pubitemid 8084847)
31. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14, 149-167. (Pubitemid 16239568)
32. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomersin human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199.
33. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100, 330-335. (Pubitemid 36078074)
34. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24, 173-182. (Pubitemid 19271472)
35. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
36. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113 Pt 21, 3737-3745.
37. Bowman GL, Dodge H, Frei B, Calabrese C, Oken BS, Kaye JA, Quinn JF (2009) Ascorbic acid and rates of cognitive decline in Alzheimer's disease. J Alzheimers Dis 16, 93-98.
38. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919. (Pubitemid 36962976)
39. Ono K, Hirohata M, Yamada M (2008) Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr Pharm Des 14, 3247-3266.
40. Yamin G, Ono K, Inayathullah M, Teplow DB (2008) Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des 14, 3231-3246.
41. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, Fan GH (2008) Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28, 11622-11634.
42. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18, 323-325.
43. Harrison FE, May JM (2009) Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 46, 719-730.
44. Harrison FE, May JM, McDonald MP (2010) Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice. Pharmacol Biochem Behav 94, 543-552.
45. Parle M, Dhingra D (2003) Ascorbic acid: a promising memory-enhancer in mice. J Pharmacol Sci 93, 129-135. (Pubitemid 37390873)
46. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24, 2716-2726.
47. Hamaguchi T, Ono K, Murase A, Yamada M (2009) Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175, 2557-2565.
48. Marlatt M, Lee HG, Perry G, Smith MA, Zhu X (2004) Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta Neurobiol Exp (Wars) 64, 81-87. (Pubitemid 38453808)
49. Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 10311-10324. (Pubitemid 47093410)